Light Induced Activation of Fusarochromanone and its Derivatives for their Use in the Diagnosis and Treatment of Cancer


Reference #: 00718

The University of South Carolina is offering licensing opportunities for an exciting advancement in cancer treatment. Fusarochromanone is a photodynamic therapy that targets cancer cells without destroying healthy cells. It is effective in low doses and has limited side effects.

Potential Applications:

Fusarochromanone can be used in the treatment of a variety of cancers.

Advantages and Benefits:

  • Kills targeted tumor cells without killing normal cells

  • Can be administered locally and in low doses

  • Limited side affects


Cancer is the leading cause of death worldwide, and is estimated to cost over $226 billion annually. Moreover, traditional cancer treatments carry the risk of severe, life altering side effects for the patient as they destroy healthy cells with cancer cells.

Invention Description:

Fusarochromanone (FC101) is a fluorescent anti-cancer therapy. FC101 accumulates more rapidly in tumor cells than in normal cells. When exposed to light, FC101 produces a reactive oxygen species that kills the tumor cells but leaves the normal cells intact. FC101 can be administered locally and in low does to limit side effects.

Patent Information:
Title App Type Country Serial No. Patent No. File Date Issued Date Expire Date Patent Status
Use of Fusarochromanone and its Derivatives in the Diagnosis and Treatment of Cancer and Other Diseases Utility United States 12/422,590 8,344,020 4/13/2009 1/1/2013 4/13/2029  
For Information, Contact:
Technology Commercialization
University of South Carolina
Brian Furmanski
John Fuseler
Roy Wuthier
© 2024. All Rights Reserved. Powered by Inteum